# US 7,745,411 B2 · Methods for promoting erythropoiesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,411 B2
- Document ID: US7745411B2
- Status: Granted
- Kind: B2
- Application number: 11/810,560
- Filed: 2007-06-06
- Published: 2009-03-05
- Granted: 2010-06-29
- Earliest claimed: 1998-02-08
- Assignees: University of Southern California
- Inventors: Kathleen Rodgers; Gere diZerega
- Web page: https://patentgrep.com/patent/US7745411B2

## CPC

- A61K 38/085: {Angiotensins}
- A61P 7/06: Antianaemics
- C12N 5/0644: {Platelets; Megakaryocytes}
- C12N 2501/32: Angiotensins [AT], angiotensinogen
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic anemia associated with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases.

## Claims

### Claim 1

A method for treating anemia comprising administering to an anemic subject an amount effective of a peptide consisting of SEQ ID NO:4 to augment erythropoiesis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anemia comprises aplastic anemia.

### Claim 3 (depends on 1)

The method of claim 1, wherein the anemia comprises hypoplastic anemia.

### Claim 4 (depends on 1)

The method of claim 1, further comprising contacting the erythroid progenitor cells with an amount effective to augment erythropoiesis of erythropoietin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the anemia is associated with chronic renal failure.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anemia is associated with end-stage renal disease.

### Claim 7 (depends on 1)

The method of claim 1, wherein the anemia is associated with renal transplantation.

### Claim 8 (depends on 1)

The method of claim 1, wherein the anemia is associated with cancer.

### Claim 9 (depends on 1)

The method of claim 1, wherein the anemia is associated with acquired immune deficiency syndrome.

### Claim 10 (depends on 1)

The method of claim 1, wherein the anemia is associated with chemotherapy.

### Claim 11 (depends on 1)

The method of claim 1, wherein the anemia is associated with radiotherapy.

### Claim 12 (depends on 1)

The method of claim 1, wherein the anemia is associated with bone marrow transplantation.